{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T15:57:31Z","timestamp":1773849451857,"version":"3.50.1"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T00:00:00Z","timestamp":1724371200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Alpha-synuclein oligomers (o-\u03b1-syn) are pivotal in the pathogenesis of \u03b1-synucleinopathy. Isolated rapid eye movement (REM) sleep behavior disorder (iRBD) serves as an early indicator of the disease, offering insights into disease mechanisms and early intervention. Nevertheless, the diagnostic and predictive potential of o-\u03b1-syn in iRBD remains largely unexplored. This study aimed to evaluate the plasma levels of o-\u03b1-syn in patients and investigate their utility as biomarkers for diagnosis of and predicting phenoconversion in iRBD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A total of 143 participants, including 77 polysomnography-confirmed iRBD patients and 66 normal controls (NC), were recruited for this longitudinal observational study. Baseline clinical assessments and plasma collection were conducted for all iRBD patients, with 72 of them undergoing regularly prospective follow-up assessments for parkinsonism or dementia. Plasma levels of o-\u03b1-syn were quantified using enzyme-linked immunosorbent assay, and were compared between groups using a general linear model adjusted for age and sex. The diagnostic performance of plasma o-\u03b1-syn in iRBD was evaluated by area under the receiver operating characteristic curve (AUC) with 95% CI. Cox regression analysis and Kaplan\u2013Meier survival curves were employed to assess the predictive value of plasma o-\u03b1-syn for phenoconversion in iRBD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Plasma o-\u03b1-syn levels did not exhibit statistically significant differences among iRBD converter patients, iRBD nonconverter patients, and NC. The AUC for distinguishing NC from iRBD was 0.52 (95% CI: 0.42\u20130.62, <jats:italic>p<\/jats:italic>\u2009=\u20090.682). Spearman correlation analysis revealed a significant positive correlation between plasma o-\u03b1-syn levels and MOCA scores in the iRBD group (<jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.001). Subgroup analyses indicated that iRBD patients with cognitive decline (<jats:italic>p<\/jats:italic>\u2009=\u20090.058) and depressive symptoms (<jats:italic>p<\/jats:italic>\u2009=\u20090.017) had notably lower o-\u03b1-syn levels compared to those without such symptoms. Over a median follow-up period of 5.83\u2009years, 26 iRBD patients developed neurodegenerative synucleinopathies. Cox regression and Kaplan\u2013Meier survival curve analyses indicated that plasma level of o-\u03b1-syn lacked a predictive value for disease conversion in iRBD patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Despite a potential role in the pathophysiology of iRBD, o-\u03b1-syn are not appropriate biomarkers for diagnosing or predicting disease progression. While this study offers insights into the pathogenesis of iRBD and neurodegenerative synucleinopathies, further large-scale longitudinal studies are warranted to validate these findings.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2024.1442173","type":"journal-article","created":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T04:50:06Z","timestamp":1724388606000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Plasma level of alpha-synuclein oligomers as a biomarker for isolated rapid eye movement sleep behavior disorder diagnosis and progression: a prospective cohort study"],"prefix":"10.3389","volume":"15","author":[{"given":"Chao","family":"Ying","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Mao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Songnian","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lifang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanning","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,8,23]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"104996","DOI":"10.1016\/j.nbd.2020.104996","article-title":"REM sleep behavior disorder (RBD)","volume":"143","author":"Hu","year":"2020","journal-title":"Neurobiol Dis"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"24351","DOI":"10.1038\/s41598-021-03751-5","article-title":"Disrupted functional connectivity in PD with probable RBD and its cognitive correlates","volume":"11","author":"Oltra","year":"2021","journal-title":"Sci Rep"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1002\/mds.28421","article-title":"Hypomethylation of SNCA in idiopathic REM sleep behavior disorder associated with Phenoconversion","volume":"36","author":"Li","year":"2021","journal-title":"Mov Disord"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"S62","DOI":"10.1016\/S1353-8020(13)70017-8","article-title":"\u03b1-Synucleinopathy phenotypes","volume":"20","author":"McCann","year":"2014","journal-title":"Parkinsonism Relat Disord"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"43495","DOI":"10.1074\/jbc.C100551200","article-title":"Stabilization of partially folded conformation during alpha-synuclein oligomerization in both purified and cytosolic preparations","volume":"276","author":"Uversky","year":"2001","journal-title":"J Biol Chem"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1523\/JNEUROSCI.4308-05.2006","article-title":"Parkinson's disease alpha-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death","volume":"26","author":"Martin","year":"2006","journal-title":"J Neurosci"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1038\/s41374-019-0195-z","article-title":"Transmission of alpha-synuclein seeds in neurodegenerative disease: recent developments","volume":"99","author":"Karpowicz","year":"2019","journal-title":"Lab Investig"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"e1267","DOI":"10.1212\/WNL.0000000000010404","article-title":"In vivo distribution of alpha-synuclein in multiple tissues and biofluids in Parkinson disease","volume":"95","author":"Chahine","year":"2020","journal-title":"Neurology"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41531-022-00357-0","article-title":"Opportunities and challenges of alpha-synuclein as a potential biomarker for Parkinson's disease and other synucleinopathies","volume":"8","author":"Magalhaes","year":"2022","journal-title":"NPJ Parkinsons Dis"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1378\/chest.14-0970","article-title":"International classification of sleep disorders-third edition: highlights and modifications","volume":"146","author":"Sateia","year":"2014","journal-title":"Chest"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1053\/j.gastro.2005.11.061","article-title":"Functional bowel disorders","volume":"130","author":"Longstreth","year":"2006","journal-title":"Gastroenterology"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1212\/01.wnl.0000324625.00404.15","article-title":"Second consensus statement on the diagnosis of multiple system atrophy","volume":"71","author":"Gilman","year":"2008","journal-title":"Neurology"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","article-title":"MDS clinical diagnostic criteria for Parkinson's disease","volume":"30","author":"Postuma","year":"2015","journal-title":"Mov Disord"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","article-title":"Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB consortium","volume":"89","author":"McKeith","year":"2017","journal-title":"Neurology"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/sleep\/zsy101","article-title":"Alpha-Synuclein aggregates in labial salivary glands of idiopathic rapid eye movement sleep behavior disorder","volume":"41","author":"Iranzo","year":"2018","journal-title":"Sleep"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1007\/s00401-019-02071-3","article-title":"Lewy-related pathology exhibits two anatomically and genetically distinct progression patterns: a population-based study of Finns aged 85","volume":"138","author":"Raunio","year":"2019","journal-title":"Acta Neuropathol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.parkreldis.2020.07.017","article-title":"Plasma immune markers in an idiopathic REM sleep behavior disorder cohort","volume":"78","author":"Zhang","year":"2020","journal-title":"Parkinsonism Relat Disord"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.nbd.2017.04.004","article-title":"Alpha-synuclein: pathology, mitochondrial dysfunction and neuroinflammation in Parkinson's disease","volume":"109","author":"Rocha","year":"2018","journal-title":"Neurobiol Dis"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S1474-4422(20)30449-X","article-title":"Detection of alpha-synuclein in CSF by RT-QuIC in patients with isolated rapid-eye-movement sleep behaviour disorder: a longitudinal observational study","volume":"20","author":"Iranzo","year":"2021","journal-title":"Lancet Neurol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1007\/s00415-014-7560-z","article-title":"Correlates of cerebrospinal fluid levels of oligomeric-and total-alpha-synuclein in premotor, motor and dementia stages of Parkinson's disease","volume":"262","author":"Compta","year":"2015","journal-title":"J Neurol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"215","DOI":"10.3988\/jcn.2011.7.4.215","article-title":"Elevated levels of alpha-synuclein oligomer in the cerebrospinal fluid of drug-naive patients with Parkinson's disease","volume":"7","author":"Park","year":"2011","journal-title":"J Clin Neurol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"4127","DOI":"10.1096\/fj.10-179192","article-title":"Phosphorylated alpha-synuclein can be detected in blood plasma and is potentially a useful biomarker for Parkinson's disease","volume":"25","author":"Foulds","year":"2011","journal-title":"FASEB J"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.neulet.2016.10.039","article-title":"Oligomeric alpha-synuclein and glucocerebrosidase activity levels in GBA-associated Parkinson's disease","volume":"636","author":"Pchelina","year":"2017","journal-title":"Neurosci Lett"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s40035-020-00192-4","article-title":"CSF total and oligomeric alpha-Synuclein along with TNF-alpha as risk biomarkers for Parkinson's disease: a study in LRRK2 mutation carriers","volume":"9","author":"Majbour","year":"2020","journal-title":"Transl Neurodegener"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/ane.13140","article-title":"The early diagnosis of Parkinson's disease through combined biomarkers","volume":"140","author":"Chen","year":"2019","journal-title":"Acta Neurol Scand"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"869797","DOI":"10.3389\/fnagi.2022.869797","article-title":"Lewy body-associated proteins A-Synuclein (a-syn) as a plasma-based biomarker for Parkinson's disease","volume":"14","author":"Zhao","year":"2022","journal-title":"Front Aging Neurosci"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"5613","DOI":"10.1007\/s00415-023-11893-x","article-title":"Combined measure of salivary alpha-synuclein species as diagnostic biomarker for Parkinson's disease","volume":"270","author":"Angius","year":"2023","journal-title":"J Neurol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"e151156","DOI":"10.1371\/journal.pone.0151156","article-title":"Abnormal salivary Total and oligomeric alpha-Synuclein in Parkinson's disease","volume":"11","author":"Vivacqua","year":"2016","journal-title":"PLoS One"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"702639","DOI":"10.3389\/fnagi.2021.702639","article-title":"Alpha-Synuclein as a biomarker of Parkinson's disease: good, but not good enough","volume":"13","author":"Ganguly","year":"2021","journal-title":"Front Aging Neurosci"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1002\/mds.27110","article-title":"Diagnostic utility of cerebrospinal fluid \u03b1-synuclein in Parkinson's disease: a systematic review and meta-analysis","volume":"32","author":"Eusebi","year":"2017","journal-title":"Mov Disord"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3390\/cells12101368","article-title":"Toll-like receptor 4 is upregulated in Parkinson's disease patients and co-localizes with pSer129alphaSyn: a possible link with the pathology","volume":"12","author":"Conte","year":"2023","journal-title":"Cells"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"67","DOI":"10.7754\/Clin.Lab.2020.200852","article-title":"Lower plasma alpha-Synuclein levels are associated with cognitive impairment in Parkinson's disease","volume":"67","author":"Song","year":"2021","journal-title":"Clin Lab"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"623977","DOI":"10.3389\/fnagi.2021.623977","article-title":"Alterations of Erythrocytic phosphorylated alpha-Synuclein in different subtypes and stages of Parkinson's disease","volume":"13","author":"Li","year":"2021","journal-title":"Front Aging Neurosci"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1093\/brain\/awac258","article-title":"Extracellular vesicle biomarkers for cognitive impairment in Parkinson's disease","volume":"146","author":"Blommer","year":"2023","journal-title":"Brain"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1136\/jnnp-2016-314857","article-title":"Plasma alpha-synuclein predicts cognitive decline in Parkinson's disease","volume":"88","author":"Lin","year":"2017","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1212\/WNL.0000000000001098","article-title":"CSF biomarkers and clinical progression of Parkinson disease","volume":"84","author":"Hall","year":"2015","journal-title":"Neurology"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S1474-4422(21)00176-9","article-title":"Biomarkers of conversion to alpha-synucleinopathy in isolated rapid-eye-movement sleep behaviour disorder","volume":"20","author":"Miglis","year":"2021","journal-title":"Lancet Neurol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1002\/mds.27806","article-title":"Longitudinal analyses of cerebrospinal fluid alpha-Synuclein in prodromal and early Parkinson's disease","volume":"34","author":"Mollenhauer","year":"2019","journal-title":"Mov Disord"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1002\/ana.24384","article-title":"Micro RNA association with synucleinopathy conversion in rapid eye movement behavior disorder","volume":"77","author":"Fernandez-Santiago","year":"2015","journal-title":"Ann Neurol"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"485","DOI":"10.3233\/JPD-223519","article-title":"Neurofilament light protein predicts disease progression in idiopathic REM sleep behavior disorder","volume":"13","author":"Zhang","year":"2023","journal-title":"J Parkinsons Dis"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.neulet.2010.06.009","article-title":"Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson's disease","volume":"480","author":"Shi","year":"2010","journal-title":"Neurosci Lett"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2024.1442173\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T04:50:08Z","timestamp":1724388608000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2024.1442173\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,23]]},"references-count":41,"alternative-id":["10.3389\/fneur.2024.1442173"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2024.1442173","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,23]]},"article-number":"1442173"}}